Who are Exacyl®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tranexamic Acid (Topical), Tranexamic Acid Injectable Solution, Topical tranexamic acid, Tranexamic Acid (IV), Tranexamic Acid Pill, Tranexamic Acid Dosage 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/exacyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Exacyl® — Competitive Intelligence Brief

Exacyl® (Exacyl®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Hematology / Hemostasis.

phase 3 Antifibrinolytic agent Plasminogen / Plasmin Hematology / Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

Exacyl® (Exacyl®) — University Hospital, Brest. Exacyl (tranexamic acid) inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Exacyl® TARGET	Exacyl®	University Hospital, Brest	phase 3	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid (Topical)	Tranexamic Acid (Topical)	Total Definer Research Group	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Injectable Solution	Tranexamic Acid Injectable Solution	Mount Sinai Hospital, Canada	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Topical tranexamic acid	Topical tranexamic acid	Aswan University Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid (IV)	Tranexamic Acid (IV)	Samsung Medical Center	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Pill	Tranexamic Acid Pill	Henry Ford Health System	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Dosage 1	Tranexamic Acid Dosage 1	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

Montefiore Medical Center · 2 drugs in this class
Pfizer · 2 drugs in this class
Hamilton Health Sciences Corporation · 2 drugs in this class
Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
Henry Ford Health System · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
NYU Langone Health · 1 drug in this class
Mount Sinai Hospital, Canada · 1 drug in this class
Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
Carlos A Acosta-Olivo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exacyl® — Competitive Intelligence Brief. https://druglandscape.com/ci/exacyl. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab